Cell Death Differ: AQP1 may be used as an indicator for predicting the sensitivity of cycloviral drugs in breast cancer patients.

Breast cancer is the most common malignant tumor in women.
is a conventional and widely used first-line chemotherapy drug for the treatment of breast cancer.
, however, a ring-based treatment can only reduce breast cancer mortality by 20 to 30 per cent, and not all breast cancer patients benefit from it, and there are no suitable biomarkers to predict the effectiveness of chemotherapy.
, a reliable marker is needed to predict a patient's sensitivity to cyclocystic drugs in order to better identify the most appropriate treatment strategy to improve patient survival.
study, researchers revealed that the AQP1 protein could be a potential reaction predictor during chemotherapy for cyclocyclin drugs.
researchers found that patients with high levels of AQP1 expression had better clinical outcomes than those with low levels of AQP1 expression in breast cancer patients treated with cyclocyclinic drugs.
mechanism studies have shown that AQP1 and GSK3 beta (glycogenase kinase 3 beta) are competitively interacted with the 12repeat sequences of beta-catenin, inhibiting the degradation of beta-catenin, which leads to beta-catenin accumulation and nuclear transport in the cytoste.
the nucleation of the beta-catenin can interact with TopoII alpha and enhance the activity of TopoII alpha, resulting in breast cancer cells being highly sensitive to cyclocyctic drugs.
researchers also found that miR-320a-3p can reduce the chemotherapy sensitivity of cyclopenoids by inhibiting the expression of AQP1.
the results of the study, which showed that AQP1 could serve as a predictive indicator in chemotherapy for cyclocyctic drugs, could help improve the prognostics of breast cancer patients who are better suited to chemotherapy with cyclocyclyctic drugs (high levels of AQP1 expression).
.